| 前收市價 | 33.10 |
| 開市 | 32.80 |
| 買盤 | 23.45 |
| 賣出價 | 24.65 |
| 拍板 | 165.00 |
| 到期日 | 2024-12-20 |
| 今日波幅 | 32.80 - 33.10 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2 |
Yahoo FinanceWalgreens cuts EPS guidance, plans to close more stores
Walgreens is closing several stores and pulling back on VillageMD locations as it restructures the company.
Investor's Business DailyEli Lilly Has Sprinted 55% Higher This Year — Is It A Buy On The Weight-Loss Opportunity?
Is Eli Lilly stock a buy as it looks to enter the obstructive sleep apnea treatment market? Is LLY stock a buy right now?
BenzingaNovo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr
